{"id":"rivaroxaban-xarelto","safety":{"commonSideEffects":[{"rate":"2-4","effect":"Bleeding (major and minor)"},{"rate":"1-2","effect":"Gastrointestinal bleeding"},{"rate":"0.5-1","effect":"Intracranial hemorrhage"},{"rate":"5-10","effect":"Dyspepsia"},{"rate":"3-5","effect":"Nausea"}]},"_chembl":{"chemblId":"CHEMBL198362","moleculeType":"Small molecule","molecularWeight":"435.89"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Rivaroxaban selectively inhibits Factor Xa, a serine protease essential for both the intrinsic and extrinsic pathways of the coagulation cascade. By blocking Factor Xa, the drug prevents the conversion of prothrombin to thrombin, thereby reducing thrombin-mediated fibrin clot formation. This anticoagulant effect is achieved with oral bioavailability and a predictable pharmacokinetic profile, eliminating the need for routine coagulation monitoring.","oneSentence":"Rivaroxaban is a direct Factor Xa inhibitor that blocks a key enzyme in the blood coagulation cascade, preventing thrombin generation and clot formation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T00:05:24.556Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Atrial fibrillation for stroke prevention"},{"name":"Deep vein thrombosis (DVT) treatment and prevention"},{"name":"Pulmonary embolism (PE) treatment and prevention"},{"name":"Acute coronary syndrome"},{"name":"Thromboprophylaxis after hip or knee replacement surgery"}]},"trialDetails":[{"nctId":"NCT05009862","phase":"PHASE4","title":"The Impact of Factor Xa Inhibition on Thrombosis, Platelet Activation, and Endothelial Function in Peripheral Artery Disease","status":"COMPLETED","sponsor":"Vanderbilt University Medical Center","startDate":"2022-04-19","conditions":"Peripheral Arterial Disease","enrollment":60},{"nctId":"NCT03568890","phase":"PHASE4","title":"Short-Term Anticoagulation Versus Antiplatelet Therapy for Preventing Device Thrombosis Following Left Atrial Appendage Closure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre de Recherche de l'Institut Universitaire de Cardiologie et de Pneumologie de Quebec","startDate":"2018-09-01","conditions":"Left Atrial Appendage Closure, Thrombosis, Stroke","enrollment":510},{"nctId":"NCT07497165","phase":"","title":"Epunamin Combined With DECP for Relapsed/Refractory Multiple Myeloma","status":"RECRUITING","sponsor":"Shanxi Bethune Hospital","startDate":"2025-11-01","conditions":"Relapsed/Refractory Multiple Myeloma (RRMM), Multiple Myeloma","enrollment":48},{"nctId":"NCT07497893","phase":"NA","title":"FENOX Trial (Comparative Effectiveness of Fexuprazan Co-therapy in Patients Receiving Non-Vitamin K Antagonist Oral Anticoagulants)","status":"NOT_YET_RECRUITING","sponsor":"Ewha Womans University Mokdong Hospital","startDate":"2026-12-01","conditions":"Atrial Fibrillation (AF), Upper Gastrointestinal Bleeding (UGIB), Gastrointestinal Hemorrhage (Clinically Important, Upper)","enrollment":1000},{"nctId":"NCT05387954","phase":"PHASE3","title":"PFO Closure, Oral Anticoagulants or Antiplatelet Therapy After PFO-associated Stroke in Patients Aged 60 to 80 Years","status":"RECRUITING","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2023-07-07","conditions":"Cryptogenic Ischemic Stroke, Patent Foramen Ovale","enrollment":792},{"nctId":"NCT03969953","phase":"PHASE3","title":"Treatment of Cardiovascular Disease With Low Dose Rivaroxaban in Advanced Chronic Kidney Disease","status":"COMPLETED","sponsor":"The George Institute","startDate":"2021-01-18","conditions":"Chronic Kidney Diseases, Dialysis-dependent Kidney Failure, Cardiovascular Disease","enrollment":1753},{"nctId":"NCT05198960","phase":"PHASE3","title":"AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms","status":"RECRUITING","sponsor":"University Hospital, Brest","startDate":"2022-07-13","conditions":"Polycythemia Vera, Essential Thrombocythemia, Prefibrotic/Early Primary Myelofibrosis","enrollment":1308},{"nctId":"NCT06650501","phase":"PHASE4","title":"Dabigatran vs. Oral Anti-Xa Inhibitors in S. Aureus Bacteremia","status":"RECRUITING","sponsor":"McGill University Health Centre/Research Institute of the McGill University Health Centre","startDate":"2026-01-15","conditions":"Staphylococcus Aureus Endocarditis, Staphylococcus Aureus Septicemia, Staphylococcus Aureus Bacteremia","enrollment":300},{"nctId":"NCT06193863","phase":"","title":"An Observational Study to Learn More About How Safe Rivaroxaban is And How Well it Works in Children With Congenital Heart Disease Who Had a Heart Surgery Called the Fontan Procedure","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2024-06-18","conditions":"Prevention of Venous Thromboembolism, Congenital Heart Disease, Fontan Procedure","enrollment":61},{"nctId":"NCT05900388","phase":"","title":"A Study to Observe the Pattern of Use and Safety of Rivaroxaban in Children Under 2 Years Old With Venous Thromboembolism (VTE)","status":"NOT_YET_RECRUITING","sponsor":"Bayer","startDate":"2026-09-01","conditions":"Venous Thromboembolism, Children Under 2 Years","enrollment":850},{"nctId":"NCT07456085","phase":"PHASE3","title":"Rivaroxaban vs Warfarin in Patients With Mechanical Heart Valves","status":"ENROLLING_BY_INVITATION","sponsor":"Rawalpindi Institute of Cardiology","startDate":"2025-11-13","conditions":"Valvular Heart Disease Patients","enrollment":60},{"nctId":"NCT07468448","phase":"PHASE3","title":"Combination Antithrombotic Treatment for Prevention of Recurrent Ischemic Stroke in IntraCranial Atherosclerotic diseaSe (CATIS- ICAS)","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2026-05-30","conditions":"Ischemic Stroke, Intracranial Atherosclerosis","enrollment":1172},{"nctId":"NCT04618913","phase":"","title":"Anticoagulation in Patients With Venous Thromboembolism and Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2020-12-14","conditions":"Neoplasms, Embolism","enrollment":1},{"nctId":"NCT05038228","phase":"","title":"High Gastrointestinal Bleed Risk Outcomes in Patients With Non-valvular Atrial Fibrillation (NVAF) in France","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2022-08-01","conditions":"Atrial Fibrillation","enrollment":1},{"nctId":"NCT05047172","phase":"PHASE3","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Florida","startDate":"2022-08-02","conditions":"Intracranial Arteriosclerosis, Stroke","enrollment":1683},{"nctId":"NCT06901466","phase":"PHASE4","title":"STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients With an Indication for Oral Anticoagulant","status":"RECRUITING","sponsor":"Chinese Academy of Medical Sciences, Fuwai Hospital","startDate":"2025-06-13","conditions":"Mitral Regurgitation","enrollment":880},{"nctId":"NCT06055920","phase":"NA","title":"The PEERLESS II Study","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-11-17","conditions":"Pulmonary Embolism","enrollment":1200},{"nctId":"NCT07246005","phase":"PHASE2","title":"LVT DURATION: Pilot Study of Anticoagulation Duration for Left Ventricular Thrombus","status":"NOT_YET_RECRUITING","sponsor":"Queen Mary University of London","startDate":"2026-12-01","conditions":"Left Ventricular Thrombus","enrollment":120},{"nctId":"NCT04874428","phase":"PHASE1","title":"Direct Oral Anticoagulants (Rivaroxaban and Apixaban) in Patients With Liver Cirrhosis","status":"RECRUITING","sponsor":"Insel Gruppe AG, University Hospital Bern","startDate":"2021-05-19","conditions":"Liver Cirrhosis","enrollment":24},{"nctId":"NCT07242326","phase":"","title":"SNAP AF-52: Dose Appropriateness and Adherence to Oral Anticoagulation in Adults ≥65 With Atrial Fibrillation in Primary Care (Ordu, Türkiye)","status":"ENROLLING_BY_INVITATION","sponsor":"Kotyora Family Medicine Health Management and Education Association","startDate":"2025-12-15","conditions":"Medication Adherence, Atrial Fibrillation (AF), Direct Oral Anticoagulants (DOACs)","enrollment":1000},{"nctId":"NCT04611893","phase":"","title":"Monitoring of NOAC Therapy: Standardizing Reference Intervals","status":"COMPLETED","sponsor":"Chinese University of Hong Kong","startDate":"2020-11-05","conditions":"Ischemic Stroke, Stroke, Acute, Stroke Syndrome","enrollment":308},{"nctId":"NCT07312851","phase":"PHASE1","title":"A Study to Investigate Andexanet Dosing and the Interaction Between Andexanet and Subsequent Enoxaparin in Healthy Participants","status":"RECRUITING","sponsor":"AstraZeneca","startDate":"2026-01-19","conditions":"Healthy Participants","enrollment":186},{"nctId":"NCT04990791","phase":"PHASE4","title":"WILL lOWer Dose Aspirin be Better With Rivaroxaban in Patients With Chronic Coronary Syndromes?","status":"COMPLETED","sponsor":"Sheffield Teaching Hospitals NHS Foundation Trust","startDate":"2021-08-26","conditions":"Coronary Syndrome","enrollment":48},{"nctId":"NCT05825573","phase":"PHASE3","title":"Anticoagulation Therapy in Non-device-related Intra-cardiac Thrombus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Centre Hospitalier Universitaire de Nīmes","startDate":"2023-05-15","conditions":"Intracardiac Thrombus, STEMI, Heart Failure","enrollment":340},{"nctId":"NCT06396858","phase":"PHASE4","title":"Anti-inflammatory and Anti-thrombotic Therapy With colcHicine and Low Dose Rivaroxaban for Major Adverse Cardiovascular Events Reduction in Ischemic Stroke","status":"NOT_YET_RECRUITING","sponsor":"Brazilian Clinical Research Institute","startDate":"2026-07","conditions":"Ischemic Stroke","enrollment":4500},{"nctId":"NCT07404436","phase":"PHASE4","title":"Rivaroxaban in Idiopathic Membranous Nephropathy","status":"RECRUITING","sponsor":"Beijing Friendship Hospital","startDate":"2024-01-05","conditions":"Idiopathic Membranous Nephropathy","enrollment":134},{"nctId":"NCT06953726","phase":"PHASE4","title":"Comparing the Safety and Efficacy of Apixaban and Rivaroxaban","status":"NOT_YET_RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2026-03-30","conditions":"Atrial Fibrillation","enrollment":10000},{"nctId":"NCT05701917","phase":"NA","title":"DEFIANCE: RCT of ClotTriever System Versus Anticoagulation In Deep Vein Thrombosis","status":"RECRUITING","sponsor":"Inari Medical","startDate":"2023-01-06","conditions":"Venous Thromboembolism, Deep Venous Thrombosis, Post-Thrombotic Syndrome","enrollment":300},{"nctId":"NCT07358416","phase":"","title":"Complications and Antiplatelet and Anticoagulant Therapy in Vascular Surgery.","status":"ACTIVE_NOT_RECRUITING","sponsor":"Petrovsky National Research Centre of Surgery","startDate":"2025-05-01","conditions":"Thrombosis, Bleeding, Cerebral Hypoxia During and/or Resulting From A Procedure","enrollment":500},{"nctId":"NCT04045665","phase":"PHASE3","title":"Anticoagulation for New-Onset Post-Operative Atrial Fibrillation After CABG","status":"RECRUITING","sponsor":"Icahn School of Medicine at Mount Sinai","startDate":"2019-12-13","conditions":"Atrial Fibrillation, Stroke, Bleeding","enrollment":3200},{"nctId":"NCT07352358","phase":"PHASE4","title":"Randomized Trial of Anticoagulation Plus Batroxobin for Acute Cerebral Venous Thrombosis","status":"RECRUITING","sponsor":"Xuanwu Hospital, Beijing","startDate":"2026-01-30","conditions":"Cerebral Venous Thrombosis","enrollment":72},{"nctId":"NCT03968393","phase":"PHASE4","title":"Anticoagulation for Stroke Prevention In Patients With Recent Episodes of Atrial Fibrillation Occurring Transiently With Stress","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2019-06-14","conditions":"Stroke, Atrial Fibrillation","enrollment":2270},{"nctId":"NCT06370273","phase":"PHASE3","title":"Thromboprophylaxis in Lower Limb Immobilisation","status":"RECRUITING","sponsor":"Queen Mary University of London","startDate":"2024-11-12","conditions":"Thrombosis, Injury Leg","enrollment":10044},{"nctId":"NCT07318610","phase":"PHASE3","title":"Reducing Adverse Vascular Outcomes With Factor XI Inhibition in Adult Participants With Peripheral Artery Disease","status":"NOT_YET_RECRUITING","sponsor":"Regeneron Pharmaceuticals","startDate":"2026-03-31","conditions":"Peripheral Artery Disease (PAD)","enrollment":7050},{"nctId":"NCT07316270","phase":"NA","title":"SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracerebral Hemorrhage (SAFER-AF)","status":"NOT_YET_RECRUITING","sponsor":"Beijing Anzhen Hospital","startDate":"2026-01","conditions":"AF - Atrial Fibrillation, ICH - Intracerebral Hemorrhage","enrollment":646},{"nctId":"NCT04258488","phase":"PHASE4","title":"Long-term Anticoagulation With Oral Factor Xa Inhibitor Versus Vitamin K Antagonist After Mechanical Aortic Valve Replacement","status":"RECRUITING","sponsor":"Joon Bum Kim","startDate":"2022-02-21","conditions":"AORTIC VALVE DISEASES, Thromboembolism","enrollment":1300},{"nctId":"NCT07270263","phase":"NA","title":"Reduced-Dose Apixaban and Rivaroxaban Versus Low-Molecular-Weight Heparin in Patients With Hematologic Malignancies","status":"RECRUITING","sponsor":"Medical University of Gdansk","startDate":"2024-11-22","conditions":"Lymphoma, Leukemia, Multiple Myeloma (MM), Lymphoma, Large B-Cell, Diffuse (DLBCL), Lymphoma","enrollment":100},{"nctId":"NCT05838664","phase":"","title":"A Study to Learn About the Effects of Medicines That Help in Thinning the Blood in People With Atrial Fibrillation (AF) Between 2016 and 2020 in France","status":"COMPLETED","sponsor":"Pfizer","startDate":"2023-07-07","conditions":"Atrial Fibrillation","enrollment":2140403},{"nctId":"NCT03463317","phase":"PHASE4","title":"Left Atrial Appendage CLOSURE in Patients With Atrial Fibrillation Compared to Medical Therapy","status":"COMPLETED","sponsor":"Charite University, Berlin, Germany","startDate":"2018-02-28","conditions":"Atrial Fibrillation","enrollment":912},{"nctId":"NCT06195540","phase":"PHASE3","title":"RIVAroxaban Versus Low-molecular Weight Heparin in Patients With Lower Limb Trauma Requiring Brace or CASTing","status":"RECRUITING","sponsor":"University Hospital, Angers","startDate":"2024-07-19","conditions":"Venous Thromboembolism, Deep Vein Thrombosis, Pulmonary Embolism","enrollment":1424},{"nctId":"NCT04180436","phase":"PHASE1","title":"Pharmacokinetics of Rivaroxaban After Bariatric Surgery","status":"COMPLETED","sponsor":"University Hospital, Brest","startDate":"2020-01-15","conditions":"Bariatric Surgery, Morbid Obesity","enrollment":67},{"nctId":"NCT02921022","phase":"NA","title":"Study Of Gemcitabine, Nab-paclitaxel, PEGPH20 and Rivaroxaban for Advanced Pancreatic Adenocarcinoma","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2016-10","conditions":"Pancreatic Cancer, Advanced Pancreatic Ductal Adenocarcinoma","enrollment":110},{"nctId":"NCT02810704","phase":"PHASE4","title":"Comparative Effectiveness of Pulmonary Embolism Prevention After Hip and Knee Replacement","status":"COMPLETED","sponsor":"Dartmouth-Hitchcock Medical Center","startDate":"2016-12","conditions":"Pulmonary Embolism, Venous Thrombosis","enrollment":18883},{"nctId":"NCT07243080","phase":"PHASE4","title":"Comparative Efficacy of Rivaroxaban and Enoxaparin in Post-Laparotomy DVT Prevention","status":"RECRUITING","sponsor":"Mayo Hospital Lahore","startDate":"2025-10-10","conditions":"Deep Venous Thromboses, Laparotomy Patients","enrollment":212},{"nctId":"NCT02559856","phase":"PHASE4","title":"Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2016-05","conditions":"Venous Thromboembolism","enrollment":72},{"nctId":"NCT04642430","phase":"PHASE4","title":"COmparison of Bleeding Risk Between Rivaroxaban and Apixaban in Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2021-07-06","conditions":"Atrial Fibrillation","enrollment":3018},{"nctId":"NCT03266783","phase":"PHASE4","title":"Comparison of Bleeding Risk Between Rivaroxaban and Apixaban for the Treatment of Acute Venous Thromboembolism","status":"COMPLETED","sponsor":"Ottawa Hospital Research Institute","startDate":"2017-12-13","conditions":"Venous Thromboembolism","enrollment":2760},{"nctId":"NCT07228663","phase":"PHASE3","title":"Hip Fracture Surgery Arterial and Venous Thrombotic Events Prevention","status":"NOT_YET_RECRUITING","sponsor":"McMaster University","startDate":"2025-12-01","conditions":"Hip Fracture Surgery, Cardiovascular Prevention, Venous Thromboembolism (VTE)","enrollment":100},{"nctId":"NCT04755283","phase":"PHASE2","title":"Safety and Tolerability of Abelacimab (MAA868) vs. Rivaroxaban in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Anthos Therapeutics, Inc.","startDate":"2021-02-02","conditions":"Atrial Fibrillation (AF), Stroke","enrollment":1287},{"nctId":"NCT04684212","phase":"NA","title":"Can the Lambre Device Occlude IRRegular And Large Appendages in Patients With Non-Valvular AF","status":"WITHDRAWN","sponsor":"Brian O'Neill MD","startDate":"2024-06-01","conditions":"Atrial Fibrillation, Left Atrial Appendage Thrombosis, CVA","enrollment":""},{"nctId":"NCT06961630","phase":"EARLY_PHASE1","title":"Post-Operative Biomarker-Guided Precision Medicine For Cardiovascular Risk Reduction","status":"RECRUITING","sponsor":"NYU Langone Health","startDate":"2025-10-07","conditions":"Myocardial Injury After Noncardiac Surgery","enrollment":50},{"nctId":"NCT07142655","phase":"","title":"An Observational Study to Learn More About the Safety of Rivaroxaban in Participants With Peripheral Arterial Disease Who Had Surgery to Improve Blood Flow to Their Legs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2025-08-12","conditions":"Peripheral Arterial Disease (PAD)","enrollment":1500},{"nctId":"NCT02168829","phase":"PHASE4","title":"Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial","status":"COMPLETED","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2016-01","conditions":"Atrial Fibrillation, Stroke","enrollment":1284},{"nctId":"NCT07202897","phase":"PHASE3","title":"LA-HCM Study : Rivaroxaban for Antithrombotic Prevention in Hypertrophic Cardiomyopathy Patients With Abnormal Left Atrial Strain.","status":"NOT_YET_RECRUITING","sponsor":"Rennes University Hospital","startDate":"2025-10-01","conditions":"Hypertrophic Cardiomyopathy (HCM)","enrollment":532},{"nctId":"NCT04284839","phase":"PHASE3","title":"The Direct Oral Anticoagulation Versus Vitamin K Antagonist After Cardiac Surgery Trial","status":"RECRUITING","sponsor":"Population Health Research Institute","startDate":"2021-07-18","conditions":"Bleeding Post Cardiac Surgery, Indication for Anticoagulation","enrollment":3500},{"nctId":"NCT07195812","phase":"PHASE4","title":"Rivaroxaban for Slow Coronary Flow After PCI in STEMI","status":"NOT_YET_RECRUITING","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2025-10","conditions":"ST Elevation Myocardial Infarction, No-Reflow Phenomenon","enrollment":60},{"nctId":"NCT04694248","phase":"NA","title":"Anticoagulant Plus Antiplatelet Therapy Following Iliac Vein Stenting","status":"RECRUITING","sponsor":"First Affiliated Hospital of Zhejiang University","startDate":"2021-11-03","conditions":"Deep Vein Thrombosis, Iliac Vein Thrombosis, Iliac Vein Obstruction","enrollment":172},{"nctId":"NCT05180773","phase":"PHASE4","title":"Impact of Bromocriptine on Clinical Outcomes for Peripartum Cardiomyopathy","status":"RECRUITING","sponsor":"Dennis M. McNamara, MD, MS","startDate":"2022-07-27","conditions":"Peripartum Cardiomyopathy, Postpartum","enrollment":250},{"nctId":"NCT06184204","phase":"","title":"Observational Study:Safety,Efficacy and Quality of Life of Patients With Atrial Fibrillation, Treated With Trombix®","status":"COMPLETED","sponsor":"Beker Laboratories","startDate":"2023-12-18","conditions":"Atrial Fibrillation","enrollment":398},{"nctId":"NCT07012291","phase":"","title":"Clinical Performance Evaluation of Native Whole Blood Samples of Patients on DOACs With the Perosphere ClotChek™","status":"RECRUITING","sponsor":"Perosphere Technologies Inc.","startDate":"2025-06-20","conditions":"Coagulation","enrollment":150},{"nctId":"NCT07173075","phase":"NA","title":"Evaluation of the Relationship Between Muscle Mass Measured by Bioelectrical Impedance Analysis and the Risk of Hemorrhagic Events Under Direct Oral Anticoagulants in the Elderly","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Clermont-Ferrand","startDate":"2025-10","conditions":"Direct Oral Anticoagulant, Hemmorhage, Elderly","enrollment":110},{"nctId":"NCT06517563","phase":"PHASE1","title":"Effects of VMX-C001 on the Anticoagulant Effect of Different Forms of Heparin","status":"ACTIVE_NOT_RECRUITING","sponsor":"VarmX B.V.","startDate":"2024-08-14","conditions":"Coagulation Disorder","enrollment":16},{"nctId":"NCT06978439","phase":"PHASE4","title":"Model-informed Dose Optimization for Rivaroxaban in Children With Giant Coronary Artery Aneurysm After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2024-01-10","conditions":"Kawasaki Disease, Pilot Study, Coronary Artery Aneurysm","enrollment":10},{"nctId":"NCT06581965","phase":"PHASE4","title":"inDividual, Targeted thrombosIS Prophylaxis Versus the Standard 'One Size Fits All' Approach in Patients Undergoing Total hIp or Total kNee replaCemenT","status":"RECRUITING","sponsor":"Leiden University Medical Center","startDate":"2024-11-11","conditions":"Venous Thromboembolism, Venous Thromboses, Pulmonary Embolism","enrollment":10078},{"nctId":"NCT03172910","phase":"PHASE2","title":"Phase 2 Study of Rivaroxaban Reversal by Ciraparantag as Measured by WBCT","status":"COMPLETED","sponsor":"Perosphere Pharmaceuticals Inc, a wholly owned subsidiary of AMAG Pharmaceuticals, Inc.","startDate":"2017-05-08","conditions":"Healthy","enrollment":69},{"nctId":"NCT06783868","phase":"","title":"Assessing the Neurological Outcomes After Atrial Fibrillation Ablation for Rhythm Control","status":"NOT_YET_RECRUITING","sponsor":"Kansas City Heart Rhythm Research Foundation","startDate":"2025-10","conditions":"Atrial Fibrillation, Stroke","enrollment":100},{"nctId":"NCT05907629","phase":"","title":"Comparison of Anti-coagulation and Anti-Platelet Therapies for Intracranial Vascular Atherostenosis- Magnetic Resonance Imaging","status":"RECRUITING","sponsor":"Yale University","startDate":"2024-06-24","conditions":"Stroke, Intracranial Atherosclerotic Stenosis (ICAS)","enrollment":300},{"nctId":"NCT05576766","phase":"NA","title":"Enhanced Recovery After Surgery (ERAS) Pathway in Patients Undergoing Robot-Assisted Laparoscopic Radical Prostatectomy","status":"NOT_YET_RECRUITING","sponsor":"Peking University First Hospital","startDate":"2025-09","conditions":"Prostate Cancer, Robot-Assisted Laparoscopic Radical Prostatectomy, Enhanced Recovery After Surgery (ERAS) Protocol","enrollment":54},{"nctId":"NCT03749057","phase":"PHASE4","title":"Early Rivaroxaban for Acute Ischemic Stroke or TIA Patients With Atrial Fibrillation","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2018-11-20","conditions":"Cerebral Infarction, TIA","enrollment":400},{"nctId":"NCT06965998","phase":"PHASE2, PHASE3","title":"A Pilot Trial Comparing Full Dose Rivaroxaban to Prophylactic Dose Rivaroxaban in Patients With Superficial Vein Thrombosis in the Leg","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2025-08-06","conditions":"SVT, Thrombosis, Superficial Vein Thrombosis","enrollment":50},{"nctId":"NCT07083609","phase":"","title":"Treatment Outcomes of Direct Oral Anticoagulants in Cerebral Venous Thrombosis in Vietnam","status":"RECRUITING","sponsor":"Hieu Trung Dinh","startDate":"2025-07-11","conditions":"Cerebral Venous Thrombosis","enrollment":69},{"nctId":"NCT07077954","phase":"PHASE1","title":"COMPARISON OF WARFARIN AND RIVAROXABAN IN THE TREATMENT OF LOWER LIMB DEEP VENOUS THROMBOSIS","status":"COMPLETED","sponsor":"Children Hospital and Institute of Child Health, Lahore","startDate":"2023-01-20","conditions":"Deep Vein Thrombosis (DVT)","enrollment":74},{"nctId":"NCT06220123","phase":"PHASE2","title":"A Study to Evaluate the Efficacy and Safety of SHR-2004 Injection in Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","status":"COMPLETED","sponsor":"Beijing Suncadia Pharmaceuticals Co., Ltd","startDate":"2024-02-16","conditions":"Preventing Postoperative Venous Thromboembolism in Patients Undergoing Ovarian Cancer Surgery","enrollment":225},{"nctId":"NCT06580223","phase":"PHASE3","title":"Aspirin or Rivaroxaban Thromboprophylaxis for Patients With Multiple Myeloma","status":"NOT_YET_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2025-09-01","conditions":"Multiple Myeloma, Venous Thromboembolism","enrollment":530},{"nctId":"NCT06831474","phase":"PHASE1","title":"Excretion of Rivaroxaban in Human Breast Milk","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2025-07","conditions":"Postpartum, VTE Prophylaxis, VTE (Venous Thromboembolism)","enrollment":10},{"nctId":"NCT06444178","phase":"PHASE1","title":"Assessment of Gastrointestinal Blood Loss After Receiving Aspirin or Aspirin Plus Rivaroxaban, or Aspirin Plus REGN9933, or Aspirin Plus REGN7508 in Healthy Adult Participants","status":"COMPLETED","sponsor":"Regeneron Pharmaceuticals","startDate":"2024-09-30","conditions":"Healthy Volunteers","enrollment":224},{"nctId":"NCT05990894","phase":"","title":"Steroid for Treatment of Acute/Subacute Severe Cerebral Venous Thrombosis.","status":"COMPLETED","sponsor":"Xuanwu Hospital, Beijing","startDate":"2020-07-01","conditions":"Cerebral Venous Thrombosis","enrollment":170},{"nctId":"NCT05920343","phase":"PHASE2, PHASE3","title":"VTE Prevention With Rivaroxaban in Genitourinary Cancer Patients Receiving Systemic Therapy","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2024-11-04","conditions":"Venous Thromboembolism, Urologic Cancer","enrollment":120},{"nctId":"NCT05029063","phase":"PHASE3","title":"Primary Thromboprophylaxis in Patients With Malignancy and Central Venous Catheters","status":"RECRUITING","sponsor":"Ottawa Hospital Research Institute","startDate":"2022-10-05","conditions":"Venous Thromboembolism, Cancer","enrollment":1828},{"nctId":"NCT03778502","phase":"","title":"DOAC in Unusual Site Venous Thrombosis","status":"COMPLETED","sponsor":"University of Malta","startDate":"2019-10-01","conditions":"Splanchnic Vein Thrombosis, Cerebral Vein Thrombosis, Ovarian Vein Thrombosis","enrollment":358},{"nctId":"NCT04486859","phase":"NA","title":"Postoperative Thrombosis Prevention in Patients With CD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Huashan Hospital","startDate":"2020-12-01","conditions":"Cushing Disease, DVT, Pulmonary Embolism","enrollment":206},{"nctId":"NCT05643651","phase":"PHASE4","title":"Rivaroxaban for Children Aged Over 2 Years With Giant Coronary Artery Aneurysms After Kawasaki Disease","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2025-06-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm","enrollment":100},{"nctId":"NCT03087487","phase":"","title":"Clinical and Economic Outcomes of Oral Anticoagulants in Non-valvular Atrial Fibrillation","status":"COMPLETED","sponsor":"Bristol-Myers Squibb","startDate":"2016-06-01","conditions":"Non-Valvular Atrial Fibrillation","enrollment":466991},{"nctId":"NCT07032025","phase":"EARLY_PHASE1","title":"Mechanical Thrombectomy for Acute Pulmonary Embolism","status":"NOT_YET_RECRUITING","sponsor":"RenJi Hospital","startDate":"2025-07-01","conditions":"Acute Pulmonary Embolism","enrollment":200},{"nctId":"NCT05622500","phase":"NA","title":"Best Endovenous Treatment, Including STenting, Versus Non-endovenous Treatment in Chronic Proximal Deep Venous Disease","status":"TERMINATED","sponsor":"Imperial College London","startDate":"2022-09-03","conditions":"Chronic Venous Insufficiency, Chronic Venous Thrombosis, Iliac Vein Stenosis","enrollment":12},{"nctId":"NCT02387229","phase":"PHASE3","title":"Blinded Randomized Trial of Anticoagulation to Prevent Ischemic Stroke and Neurocognitive Impairment in AF","status":"TERMINATED","sponsor":"Montreal Heart Institute","startDate":"2015-03","conditions":"ATRIAL FIBRILLATION","enrollment":1238},{"nctId":"NCT06101667","phase":"NA","title":"Efficacy and Safety of Endovascular Recanalization for Acute Basilar Artery Occlusion With Extended Time Window (ANGEL-BAO)","status":"RECRUITING","sponsor":"Beijing Tiantan Hospital","startDate":"2023-10-15","conditions":"Acute Ischemic Stroke, Basilar Artery Occlusion","enrollment":224},{"nctId":"NCT07011095","phase":"EARLY_PHASE1","title":"DOAC or VKA in Patients With AF and Stroke While on DOAC - a Pilot Trial","status":"NOT_YET_RECRUITING","sponsor":"Population Health Research Institute","startDate":"2025-09-03","conditions":"Atrial Fibrillation (AF), Stroke (in Patients With Atrial Fibrillation)","enrollment":100},{"nctId":"NCT04263038","phase":"PHASE4","title":"Clinical Surveillance vs. Anticoagulation for Low-risk Patients With Isolated Subsegmental Pulmonary Embolism","status":"RECRUITING","sponsor":"Drahomir Aujesky","startDate":"2020-05-15","conditions":"Pulmonary Embolism, Embolism, Embolism and Thrombosis","enrollment":276},{"nctId":"NCT06993636","phase":"","title":"Pharmacometrics Analysis of Rivaroxaban in Chinese Children Aged Over 2 Years","status":"RECRUITING","sponsor":"Children's Hospital of Fudan University","startDate":"2023-01-01","conditions":"Kawasaki Disease, Coronary Artery Aneurysm, Rivaroxaban","enrollment":60},{"nctId":"NCT06986369","phase":"PHASE4","title":"Effects of Rivaroxaban on Vascular FMD in Patients With Stable Atherosclerotic Vascular Diseases","status":"COMPLETED","sponsor":"The University of Hong Kong","startDate":"2021-05-04","conditions":"Atherosclerosis, Coronary","enrollment":140},{"nctId":"NCT06983795","phase":"","title":"Pioneering Advancements in Cardiocerebrovascular Interactions in the Asia pacFIC - Patent Foramen Ovale Study","status":"NOT_YET_RECRUITING","sponsor":"National University Hospital, Singapore","startDate":"2025-07","conditions":"Ischemic Stroke, Patent Foramen Ovale","enrollment":1000},{"nctId":"NCT03129490","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Atrial Fibrillation","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Atrial Fibrillation, Atrial Flutter","enrollment":11000},{"nctId":"NCT04700826","phase":"PHASE4","title":"Preventing Stroke, Premature Death and Cognitive Decline in a Broader Community of Patients With Atrial Fibrillation","status":"RECRUITING","sponsor":"University of Birmingham","startDate":"2021-06-01","conditions":"Atrial Fibrillation","enrollment":3000},{"nctId":"NCT03630055","phase":"PHASE3","title":"Rivaroxaban Post-Transradial Access for the Prevention of Radial Artery Occlusion","status":"RECRUITING","sponsor":"Ottawa Heart Institute Research Corporation","startDate":"2018-10-03","conditions":"Radial Artery Occlusion","enrollment":1800},{"nctId":"NCT03129555","phase":"PHASE4","title":"The Danish Non-vitamin K Antagonist Oral Anticoagulation Study in Patients With Venous Thromboembolism (DANNOAC-VTE)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Herlev and Gentofte Hospital","startDate":"2023-04-01","conditions":"Deep Vein Thrombosis, Pulmonary Embolism","enrollment":5000},{"nctId":"NCT05588284","phase":"NA","title":"Preservation of Venous Valvular Function After PMT for Acute DVT","status":"ENROLLING_BY_INVITATION","sponsor":"Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University","startDate":"2022-06-06","conditions":"Acute Deep Venous Thrombosis of Femoral Vein (Disorder)","enrollment":100},{"nctId":"NCT05794399","phase":"PHASE4","title":"Anticoagulation in Post MI LV Thrombus Trial in Nepal","status":"RECRUITING","sponsor":"Shahid Gangalal National Heart Centre","startDate":"2023-06-19","conditions":"Left Ventricular Thrombus, Myocardial Infarction","enrollment":196},{"nctId":"NCT06957366","phase":"NA","title":"Perioperative Anticoagulant Use for Surgery Evaluation -2 (PAUSE-2) Study Patients Receiving a Direct Oral Anticoagulant (DOACs-Dabigatran, Rivaroxaban, Apixaban or Edoxaban) and Needing Elective High-Bleed-Risk Surgery or an Invasive Procedure","status":"RECRUITING","sponsor":"McMaster University","startDate":"2025-04-01","conditions":"Atrial Fibrillation (AF), VTE","enrollment":920},{"nctId":"NCT05093504","phase":"NA","title":"Safe and Timely Antithrombotic Removal - Direct Oral Anticoagulants Apixaban & Rivaroxaban (STAR-D)","status":"TERMINATED","sponsor":"CytoSorbents, Inc","startDate":"2021-12-27","conditions":"Hemorrhage, Surgical, Hemorrhage Postoperative, Blood Loss, Surgical","enrollment":9}],"_emaApprovals":[],"_faersSignals":[{"count":3,"reaction":"ABDOMINAL PAIN"},{"count":3,"reaction":"ASTHENIA"},{"count":3,"reaction":"CEREBROVASCULAR ACCIDENT"},{"count":3,"reaction":"HAEMOPTYSIS"},{"count":2,"reaction":"ANAEMIA"},{"count":2,"reaction":"DEEP VEIN THROMBOSIS"},{"count":2,"reaction":"DYSPNOEA"},{"count":2,"reaction":"FATIGUE"},{"count":2,"reaction":"HAEMOGLOBIN DECREASED"},{"count":2,"reaction":"MALAISE"}],"_approvalHistory":[],"publicationCount":2,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Anticoagulation"],"phase":"marketed","status":"active","brandName":"Rivaroxaban (Xarelto)","genericName":"Rivaroxaban (Xarelto)","companyName":"University of Michigan","companyId":"university-of-michigan","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Rivaroxaban, also known as Xarelto, is a small molecule inhibitor that targets coagulation factor X. It is used to treat conditions such as deep vein thrombosis, atrial fibrillation, and may be used to prevent conditions like intracerebral hemorrhage.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}